Background
Cardiac amyloidosis (CA) is a serious and progressive infiltrative disease that is caused by the deposition of amyloid fibrils at the cardiac level.1
The diagnosis of cardiac amyloidosis depends on a high degree of clinical suspicion and is often delayed due to the lack of disease awareness and the heterogeneity of symptoms at presentation.2 By the time diagnosis is made quality of life is often poor.3 Cardiac amyloidosis tends to lead to progressive heart failure and is associated with significantly reduced survival.3
With healthcare provider interest in improving the care of patients with cardiac amyloidosis, the development of an optimal care pathway for the condition may help to reduce delays in diagnosis and treatment and thus enhance patient outcomes.3
Grant Programmes Overview
Pfizer is offering two separate grant programmes to support projects that aim to improve the identification and management of cardiac amyloidosis in the UK:
Primary Care Grant Programme
Secondary Care Grant Programme
1. Primary Care Grant Programme
Purpose
This healthcare improvement grant programme seeks to support initiatives that deliver measurable improvements in the identification and management of cardiac amyloidosis. The programme will support projects that focus on systematic reviews of heart failure patient records in primary care to identify clinical indicators (“red flags”) suggestive of cardiac amyloidosis.
Eligibility
UK-based institutions, organisations, or associations comprised of healthcare professionals and/or providing healthcare.
Grants awarded to organisations, not individuals.
Not open to commercial for-profit organisations.
Clinical Area
Heart failure, focusing on cardiac amyloidosis.
Application Criteria
Proposals should aim to improve recognition of cardiac amyloidosis in primary care.
Likely applicants: Primary Care Physicians, Heart Failure Nurses, Heart Failure Pharmacists, Allied Heart Failure Healthcare Professionals, and other relevant Healthcare professionals.
Must have a defined cardiac amyloid pathway agreed with a secondary care cardiology team, outlined in the application.
Demonstrate an established relationship with a secondary care cardiology team for ongoing patient care.
Initial audit population of at least 50,000 patients prior to stratification for those with confirmed heart failure.
Clear activity timeline with key milestones and feasibility for completion within 6 months.
A final evaluation report will be requested confirming project completion and evidencing appropriate use of funds.
Out of Scope
Projects naming specific medicines or designed to increase uptake of a single therapeutic agent.
Funding for services that should be standard within the NHS.
Interventional/observational clinical studies, animal studies, epidemiology studies, outcomes research, or independent research on disease states, novel diagnostic tools, or surveys.
Funding for hospital equipment, medical devices, or infrastructure improvements.
Funding
Individual proposals up to £10,000 considered (total programme budget: £50,000).
Pfizer maintains a company-wide, maximum allowed overhead rate of 28% for independent projects. Please click here for details.
2. Secondary Care Grant Programme
Purpose
This healthcare improvement grant seeks to support initiatives that deliver measurable improvements in the identification and management of cardiac amyloidosis within secondary care. The programme will support projects that focus on systematically reviewing at-risk patient cohorts to identify clinical indicators (“red flags”) suggestive of cardiac amyloidosis.
Eligibility
UK-based institutions, organisations, or associations comprised of healthcare professionals and/or providing healthcare.
Grants awarded to organisations, not individuals.
Not open to commercial for-profit organisations.
Clinical Area
Cardiology, focusing on cardiac amyloidosis.
Application Criteria
Proposals should aim to improve recognition of cardiac amyloidosis in secondary care.
Likely applicants: General Cardiologists, Heart Failure Cardiologists, Heart Failure Nurses, Heart Failure Pharmacists, Echocardiographers, Electrophysiologists, , Allied Heart Failure Healthcare Professionals, Internal Medicine Specialists, Interventional Cardiologists, Nuclear Cardiologists, Nuclear Medicine Specialists, Research Fellows, and other relevant Healthcare professionals.
Must have a defined cardiac amyloid pathway including a referral process to one of the commissioned amyloidosis centres in England (National Amyloidosis Centre, Liverpool, Birmingham).
Outline the size and definition of the patient cohort available for audit, including expected patient numbers.
Clear activity timeline with key milestones and feasibility for completion within 6 months.
A final evaluation report will be requested confirming project completion and evidencing appropriate use of funds.
Out of Scope
Projects naming specific medicines or designed to increase uptake of a single therapeutic agent.
Funding for services that should be standard within the NHS.
Interventional/observational clinical studies, animal studies, epidemiology studies, outcomes research, or independent research on disease states, novel diagnostic tools, or surveys.
Funding for hospital equipment, medical devices, or infrastructure improvements.
Funding
Individual proposals up to £25,000 considered (total programme budget: £100,000).
Pfizer maintains a company-wide, maximum allowed overhead rate of 28% for independent projects. Please click here for details.
Other Information
Applications must be signed by the lead physician responsible for the audited patient group.
A quantitative completion report will be required to evidence appropriate use of funds (due diligence).
To ensure equity and avoid healthcare disparities, if the applicant has received funding for similar projects from Pfizer within the previous three years, the award of a new grant will be determined on a case-by-case basis.
Sponsored healthcare professionals cannot be engaged by Pfizer for promotional activities during the grant.
In projects involving an element of therapy area review, all available products should be considered.
The requester must be affiliated to the organisation for which the request is being made and must be able to demonstrate both the awareness and support of the organisation.
Review & Notification of Grant Applications
Reviewed by Pfizer commercial, medical and compliance colleagues.
Awarded on a first-come, first-served basis, subject to criteria.
Applicants notified by email; further clarification may be requested.
When the budget is allocated, no further applications will be accepted.
Please first submit a Donations Enquiry form by clicking “Apply for the Grant Programme” below. A pfizer colleague will then reach out to share a Grant application form.
References